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428Matrix metalloproteinase 10 is associated with
disease severity and mortality in patients with
peripheral arterial disease
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Objective: Peripheral arterial disease (PAD) is associated with poor prognosis in terms of cardiovascular (CV) morbidity
and mortality. Matrix metalloproteinases (MMPs) contribute to vascular remodeling by degrading extracellular matrix
components and play a role in atherosclerosis as demonstrated for MMP-10 (stromelysin-2). This study analyzed MMP-
10 levels in PAD patients according to disease severity and CV risk factors and evaluated the prognostic value of MMP-10
for CV events and mortality in lower limb arterial disease after a follow-up period of 2 years.
Methods: MMP-10 was measured by enzyme-linked immunosorbent assay in 187 PAD patients and 200 sex-matched
controls.
Results: PAD patients presented with increased levels of MMP-10 (7026 326 pg/mL control vs 9466 473 pg/mL PAD;
P < .001) and decreased levels of tissue inhibitor of matrix metalloproteinase 1 (312 6 117 ng/mL control vs 235 6
110 ng/mL PAD; P < .001) compared with controls. Among PAD patients, those with critical limb ischemia (n [ 88)
showed higher levels of MMP-10 (1086 6 478 pg/mL vs 822 6 436 pg/mL; P < .001) compared with those with
intermittent claudication (n[ 99), whereas the MMP-10/tissue inhibitor of matrix metalloproteinase 1 ratio remained
similar. The univariate analysis showed an association between MMP-10, age (P[ .015), hypertension (P[ .021), and
ankle-brachial index (P [ .006) in PAD patients that remained signiﬁcantly associated with PAD severity after adjust-
ment for other CV risk factors. Patients with the highest MMP-10 tertile had an increased incidence of all-cause mortality
and CV mortality (P < .03).
Conclusions: Our results suggest that MMP-10 is associated with severity and poor outcome in PAD. (J Vasc Surg
2015;61:428-35.)Peripheral arterial disease (PAD) is a manifestation of
atherosclerotic vascular disease often associated with other
comorbidities, such as diabetes, dyslipidemia, and hyper-
tension. Its prevalence in Western societies increases with
age; 20% of patients older than 65 years are diagnosed
with PAD, and it is associated with a high case-fatality
rate due to cardiovascular (CV) ischemic events.1-5 PAD
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tomatic disorders may be manifested as either intermittent
claudication (IC) or critical limb ischemia (CLI), which is
the initial manifestation in roughly 1% to 2% of all patients,
with a mortality rate up to 25% at 1 year.2
An increasing body of evidence supports the notion
that inﬂammation plays an important role in the develop-
ment and progression of PAD.6 Moreover, PAD leads
to broad adaptive changes in the arterial wall and the
ischemic muscle in response to atherosclerosis and blood
ﬂow impairment, respectively. Matrix metalloproteinases
(MMPs) are a family of zinc-dependent endopeptidases
with proteolytic activity against a wide range of extracel-
lular proteins7 that contribute extensively to tissue remod-
eling by degrading extracellular matrix components in
diverse vascular pathologic processes.1,8-11 Recent clinical
studies showed an association between PAD and circu-
lating levels of MMP-2, MMP-9, and MMP-8 compared
with healthy volunteers9-12 but did not explore the involve-
ment of MMP-10 (stromelysin-2) in the development and
progression of PAD. An association has previously been
shown between MMP-10 and different inﬂammatory
markers, increased carotid intima-media thickness, and
the presence of carotid plaques in CV-risk patients free
from CV complication.13 In vivo, MMP-10 expression
has been shown in endothelial cells and macrophages
within human atherosclerotic plaques,14 and augmented
MMP-10 levels have been described in patients with
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stroke, and diabetes,15-18 suggesting a role for MMP-10
in vascular pathologic processes associated with impaired
vascular remodeling and inﬂammation.
On the basis of previous studies reporting the involve-
ment of MMP-10 in atherosclerosis and inﬂammatory dis-
eases, the working hypothesis was that MMP-10 levels are
increased in patients with symptomatic PAD, associated
with poor outcome and poor prognosis. Therefore, levels
of MMP-10 were measured in patients with PAD, with
analysis of its association with CV risk factors, inﬂammatory
markers, and subclinical atherosclerosis and its relationship
with clinical outcome after a follow-up period. In addition,
histologic analysis was performed to examine the local
expression of MMP-10 at the femoral artery of PAD
patients.
METHODS
Baseline characteristics of patients. Patients (n ¼
187) were prospectively enrolled and blood samples collected
at the time of clinical evaluation at the outpatient service of
the Department of Vascular Surgery of the Complejo Hospi-
talario de Navarra between 2010 and 2013. No patient was
included postoperatively. Patients were classiﬁed according to
the severity of the disease: IC (n ¼ 99), with a history of IC
(Fontaine class II) diagnosed by hemodynamic study
(Doppler ultrasound); and CLI (n ¼ 88), with lower limb
rest pain or trophic lesions (Fontaine class III-IV)
conﬁrmed by imaging studies (arteriography, magnetic
resonance angiography, or ultrasonography). Among those
patients belonging to Fontaine class IV, the ones with
infected lesions were excluded from the study, as were in-
dividuals with evidence of neoplastic disease, with generalized
or localized inﬂammatory disease (moderate or severe), with
severe chronic kidney disease, on hemodialysis, or receiving
anti-inﬂammatory drugs. Ankle-brachial index (ABI) was
measured at rest per standard technique in the dorsalis pedis
and posterior tibial arteries of both lower limbs.19
A thorough medical history was recorded in all patients
including details of previous myocardial infarction, arterial
hypertension, cerebrovascular disease, smoking status, dia-
betes mellitus, body mass index, and medication. Patients
actively smoking or having discontinued smoking within
2 years were considered smokers. Diabetes was deﬁned
by history of diabetes mellitus or the use of antidiabetic
drugs. Hypertension was deﬁned by any history of hyper-
tension or the use or antihypertensive drugs.
Follow-up. Patients were followed up (mean period,
27 months [range, 11-46 months]) at the outpatient service
of the Department of Vascular Surgery every 3 or 6 months,
depending on the severity of PAD. At those regular
checkups, patients were tested for biochemical parameters
and underwent physical examination and ABI measurement.
No patient was lost to follow-up. For outcome evaluation of
PAD patients, CV events and death were recorded. Major
adverse CV events (MACE), including amputation, ischemic
coronary disease, cerebrovascular disease, and all-cause
mortality as a composite end point, were deﬁned.A control group of 200 sex-matched subjects free from
clinically manifested atherosclerotic vascular disease who
attended the outpatient service of the Department of Inter-
nal Medicine at the Clínica Universidad de Navarra for a
general checkup was included.13 No follow-up of the con-
trol population was recorded.
The study was approved by the Institutional Review
Boards of the corresponding hospitals, and informed con-
sent from patients was obtained.
Laboratory analysis. Serum total cholesterol, high-
density lipoprotein cholesterol, triglycerides, and glucose
were measured in fasting blood samples by standard labo-
ratory techniques. Low-density lipoprotein cholesterol was
estimated by the Friedewald equation. Plasma ﬁbrinogen
activity was measured by clotting assay (Clauss), and high-
sensitivity C-reactive protein (hs-CRP) was measured by
immunoassay (Immulite; Diagnostic Products Corpora-
tion, Los Angeles, Calif).
MMP-10 and tissue inhibitor of matrix metal-
loproteinase 1 (TIMP-1) determination. MMP-10 and
TIMP-1 levels were assayed in serum by enzyme-linked
immunosorbent assay (Quantikine; R&D Systems, Min-
neapolis, Minn) as previously described.13,20 Interassay and
intra-assay coefﬁcients of variation for the enzyme-linked
immunosorbent assays were <6%.
Protein immunolocalization in human atheroscle-
rotic lesions. Specimens from 10 patients undergoing
femoral endarterectomy (>75% stenosis) were ﬁxed with
4% paraformaldehyde, decalciﬁed for 24 to 72 hours at
room temperature (Osteosoft, 101728; Merck Millipore,
Darmstadt, Germany), and embedded in parafﬁn. Serial
sections were analyzed by immunohistochemistry as
described21 with the following antibodies: rabbit anti-
human MMP-10 (10 mg/mL; Acris Antibodies, San
Diego, Calif) and mouse anti-human CD68 (0.6 mg/mL;
Dako, Carpinteria, Calif). Hematoxylin and eosin staining
was used to examine tissue morphologic features.
Statistical analysis. Continuous variables are presented
as mean and standard deviation. Comparisons between
more than two groups were done with analysis of variance
or c2 test for continuous or categorical variables, respec-
tively. Associations between MMP-10 levels and athero-
sclerotic risk factors or inﬂammatory markers were examined
by Pearson correlation test for continuous variables and
unpaired Student t-test for categorical variables. Receiver
operating characteristic (ROC) curves were performed to
analyze the ability of MMP-10 to identify patients with PAD
in the whole population of subjects. Binary logistic regres-
sion analysis was performed to evaluate the contribution of
MMP-10 to the risk of PAD after adjustment by CV risk
factors and inﬂammatory markers. Odds ratios and respec-
tive 95% conﬁdence intervals (CIs) obtained after adjust-
ment for relevant covariates are presented. Kaplan-Meier
estimates were used to compare time to event differences
across MMP-10 tertiles by the log-rank test. Statistical sig-
niﬁcance was established as P < .05. The statistical analysis
was performed with SPSS for Windows software package
version 15.0 (SPSS Inc, Chicago, Ill).
Table I. Demographic and clinical parameters of control
population and peripheral arterial disease (PAD) patients
Control
(n ¼ 200)
PAD
(n ¼ 187) P
Demographic and clinical data
Sex, male, % 88 88 .92
Age, years 61 (10) 71 (11) <.001
Smokers, % 30 80 <.001
Diabetes mellitus, % 15 46 <.001
Hypertension, % 49 72 <.001
Dyslipidemia, % 77 53 <.001
Treatment, %
Anticoagulants d 12
Antiplatelets d 76
ACE inhibitors 7 35 <.001
ARA-II 8 23 <.001
Calcium antagonists d 20
Vasodilators d 10
Beta blockers d 26
Statins 14 61 <.001
Laboratory data
LDL, mg/dL 144 (36) 100 (37) <.001
HDL, mg/dL 49 (13) 43 (17) <.001
Triglycerides, mg/dL 125 (65) 142 (83) .024
Fibrinogen, mg/dL 298 (94) 503 (132) <.001
hs-CRP, mg/La 4.8 (11) 17 (29) <.001
ACE, Angiotensin-converting enzyme; ARA-II, angiotensin II receptor
antagonist; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-
reactive protein; LDL, low-density lipoprotein.
Mean (standard deviation) is shown.
aSkew variable was logarithmically transformed.
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Circulating MMP-10 levels are increased in PAD
patients. MMP-10 was measured in 187 PAD patients
and 200 sex-matched controls. The baseline characteris-
tics of both groups are shown in Table I. Patients were
older (P < .001), and the prevalence of traditional CV
risk factors, such as diabetes, hypertension, and smoking,
was higher than in controls (P < .001). They were under
treatment as recommended by current guidelines. The
increased percentage of patients taking cholesterol-
lowering drugs compared with controls (statins: 61% vs
14%; P < .001) may explain the decreased levels of low-
density lipoprotein compared with healthy subjects,
although triglycerides remained higher (P < .05) and
high-density lipoprotein remained lower (P < .01).
Moreover, patients presented with increased levels of
ﬁbrinogen and hs-CRP (P < .05), as expected in a
proinﬂammatory/atherosclerotic state. Levels of MMP-10
were increased (Fig 1, A; P < .001), whereas its principal
inhibitor, TIMP-1, was decreased (Fig 1, B; P < .001),
leading to a signiﬁcantly elevated MMP-10/TIMP-1 ratio
in PAD subjects (Fig 1, C).
Binary logistic regression analysis was performed to
study the contribution of CV risk factors and MMP-10
to PAD in the whole population (n ¼ 387; Table II).
The multivariate analysis showed that not only age (P <
.001), smoking (P < .001), diabetes (P < .001), hyperten-
sion (P ¼ .004), and dyslipidemia (P < .001) but also
circulating MMP-10 levels (P ¼ .003) were signiﬁcantly
associated with PAD.
Next, to analyze the ability of MMP-10 to identify
PAD patients in the whole population (n ¼ 387; Fig 1,
D), ROC curve analysis was performed (area under the
curve, 0.674 6 0.027; 95% CI, 0.620-0.727; P < .001).
The cutoff value of 714 pg/mL for MMP-10 provided
62% speciﬁcity and 64% sensitivity for predicting PAD
with a relative risk of 2.86 (95% CI, 1.89-4.31).
Association of MMP-10 with CV risk factors and
severity of PAD. The study was then focused on the dis-
tribution of MMP-10 in PAD patients according to disease
severity. Therefore, the PAD population was stratiﬁed by
patients with IC (n ¼ 99) and those with CLI (n ¼ 88)
following the Fontaine classiﬁcation. Traditional CV risk
factors (age, diabetes, smoking, and inﬂammatory markers
ﬁbrinogen and hs-CRP) were increased in CLI patients
compared with IC patients (Table III). Similarly, circu-
lating levels of MMP-10 and TIMP-1 were also higher in
CLI patients (P < .01; Fig 1, A and B), whereas the ratio
MMP-10/TIMP-1 remained similar in both groups (Fig 1,
C). In addition, the univariate analysis showed that MMP-
10 was associated with age (r ¼ .178; P ¼ .015) and hy-
pertension (P ¼ .021) and inversely correlated with ABI
(r ¼ .239; P ¼ .006).
To study the contribution of CV risk factors and
MMP-10 to the severity of PAD, a multiple logistic regres-
sion analysis was performed with MMP-10 categorized in
tertiles: tertile 1, #678 pg/mL; tertile 2, 679-1056 pg/mL;and tertile 3, $1057 pg/mL. Higher MMP-10 levels were
associated with PAD severity (model 1, P < .001), in con-
trolling for sex and age (model 2, P < .001), and also after
introducing other traditional risk factors and inﬂammatory
markers as covariates (model 3, P < .001; Table IV).
Relationship between MMP-10 and clinical
outcome in PAD. To evaluate the association of MMP-10
with clinical outcome in PAD patients, the numbers of CV
events and death were recorded for a mean follow-up of
27 months (range, 11-46 months). Of 187 patients, 10%
(18) were subjected to amputation, 3% presented with
acute cerebrovascular events, 10% had ischemic coronary
disease, and 23% died during the follow-up. Univariate
analysis showed no association between MMP-10 and
amputation (P ¼ .121), ischemic coronary disease (P ¼
.338), or acute cerebrovascular events (P ¼ .58). MMP-10
levels, however, were signiﬁcantly increased in considering
all-cause mortality (Fig 2, A; P ¼ .021), but there was no
signiﬁcant association between MMP-10 and MACE as a
composite end point (P ¼ .067).
PAD patients were divided according to MMP-10 ter-
tiles and Kaplan-Meier analysis was performed to assess
whether the time to amputation, CV events, or mortality
was associated with MMP-10 levels. The results showed
that all-cause mortality at 24 months was 39% in subjects
with the highest levels of MMP-10 compared with the
lowest tertiles (15%; Fig 2, B; P ¼ .028). The amputation
rate at 12 months was increased in patients at the highest
Fig 1. Circulating levels of matrix metalloproteinase 10 (MMP-10) are increased in patients with peripheral arterial
disease (PAD) according to the disease severity. A, MMP-10 levels were measured in control subjects (Ctrl, n ¼ 200)
and PAD patients (n ¼ 187). PAD patients were then divided according to disease severity into intermittent claudi-
cation (IC, n¼ 99) and critical limb ischemia (CLI, n¼ 88).B, Tissue inhibitor of matrix metalloproteinase 1 (TIMP-1)
was decreased in PAD patients. C, MMP-10/TIMP-1 ratio was increased in patients compared with controls. D,
Receiver operating characteristic (ROC) curve for MMP-10 plotted for various cutoff values to determine PAD.
Table II. Logistic regression analysis to estimate the
odds ratio of peripheral arterial disease (PAD) in control
and PAD patients
Beta estimate (95% CI) P
Sex, male 1.11 (0.47-2.57) .809
Age 1.09 (1.06-1.13) <.001
Smokers 17.11 (8.27-35.41) <.001
Diabetes mellitus 4.06 (2.06-7.97) <.001
Hypertension 2.42 (1.30-4.50) .005
Dyslipidemia 0.27 (0.14-0.52) <.001
MMP-10 1.001 (1.000-1.002) .003
CI, Conﬁdence interval; MMP-10, matrix metalloproteinase 10.
Dependent variable control/PAD.
JOURNAL OF VASCULAR SURGERY
Volume 61, Number 2 Martinez-Aguilar et al 431tertile compared with those in the lower ones (17% vs 7%;
Fig 2, C; P ¼ .092). Finally, the time to event for MACE
was determined as a composite end point. At 24 months,
51% of the patients at the highest MMP-10 tertile suffered
MACE, whereas the percentage was lower in those at the
lowest tertiles (25% and 24%; P ¼ .015). No differences in
cerebrovascular events (P ¼ .715) or ischemic coronary dis-
ease (P ¼ .109) were reported among tertiles of MMP-10.
Because 57% of deaths were related to CV mortality
(n ¼ 24), survival in this subgroup was studied. As shownin Fig 2, D, CV mortality at 24 months was 29% and signif-
icantly increased in patients at the highest MMP-10 tertile
compared with those at the lowest tertiles (3% and 11%;
P ¼ .017).
MMP-10 co-localizes with inﬂammatory cells in
atherosclerotic femoral arteries. Because MMP-10
expression had not been documented in this vascular
bed, arteries from PAD patients undergoing femoral end-
arterectomy were collected for the histologic analysis. As
shown in Fig 3, MMP-10 expression was observed in the
diseased artery wall of patients, being localized at the
shoulder of the atherosclerotic lesion close to macrophage
(CD68þ)erich regions.
DISCUSSION
PAD is a major cause of acute and chronic illness.
Compared with patients with coronary or cerebrovascular
disease, those with PAD actually have higher rates of all-
cause mortality and major CV events.5 The current study
reports increased circulating levels of MMP-10 in PAD pa-
tients according to disease severity and in association with
poor outcome.
PAD remains highly underdiagnosed and undertreated,
which results in higher risk for adverse outcomes.1,22
Moreover, traditional atherosclerotic risk factors, such as
Table III. Baseline characteristics of intermittent
claudication (IC) and critical limb ischemia (CLI)
patients
IC (n ¼ 99) CLI (n ¼ 88) P
Demographic and clinical data
Sex, M, % 89 86 .600
Age, years 68 (10) 73 (11) .002
Smokers, % 87 72 .010
Diabetes mellitus, % 28 67 <.001
Hypertension, % 70 75 .419
Dyslipidemia, % 60 45 .053
ABI 0.61 (0.17) 0.34 (0.11) <.001
Treatment, %
Anticoagulants 8 17 .062
Antiplatelets 83 69 .030
ACE inhibitors 30 40 .175
ARA-II 19 27 .190
Calcium antagonists 18 23 .441
Vasodilators 9 11 .608
Beta blockers 18 24 .340
Statins 69 53 .032
Laboratory data
LDL, mg/dL 107 (38) 91 (34) .005
HDL, mg/dL 51 (16) 35 (13) <.001
Triglycerides, mg/dL 150 (93) 133 (69) .145
Fibrinogen, mg/dL 452 (89) 558 (149) <.001
hs-CRP, mg/La 5.5 (9) 30.1 (37) <.001
ABI, Ankle-brachial index; ACE, angiotensin-converting enzyme; ARA-II,
angiotensin II receptor antagonist; HDL, high-density lipoprotein; hs-CRP,
high-sensitivity C-reactive protein; LDL, low-density lipoprotein.
Mean (standard deviation) is shown.
aSkew variable was logarithmically transformed.
Table IV. Logistic regression analysis to estimate the
odds ratio of critical limb ischemia (CLI) in peripheral
arterial disease (PAD) patients
Beta estimate
(95% CI) P
Model 1
MMP-10 tertile 1 1.0 (reference)
MMP-10 tertile 2 1.33 (0.63-2.81) .448
MMP-10 tertile 3 6.12 (2.82-13.30) <.001
Model 2
Sex, male 0.73 (0.28-1.91) .529
Age 1.04 (1.01-1.07) .006
MMP-10 tertile 1 1.0 (reference)
MMP-10 tertile 2 1.39 (0.64-2.98) .404
MMP-10 tertile 3 5.92 (2.68-13.11) <.001
Model 3
Sex, male 1.07 (0.24-4.815) .932
Age 1.01 (0.97-1.06) .655
Smokers 0.34 (0.08-1.45) .145
Diabetes mellitus 8.12 (2.76-23.82) <.001
Hypertension 0.66 (0.22-1.93) .444
HDL 0.97 (0.94-1.01) .063
Fibrinogen 1.00 (0.99-1.00) .707
hs-CRPa 30.82 (6.09-155.92) <.001
MMP-10 tertile 1 1.0 (reference)
MMP-10 tertile 2 3.26 (0.98-10.86) .054
MMP-10 tertile 3 18.54 (5.08-67.67) <.001
CI, Conﬁdence interval; HDL, high-density lipoprotein; hs-CRP, high-
sensitivity C-reactive protein; MMP-10, matrix metalloproteinase 10.
Dependent variable intermittent claudication (IC)/CLI.
aSkew variable was logarithmically transformed.
JOURNAL OF VASCULAR SURGERY
432 Martinez-Aguilar et al February 2015diabetes mellitus, cigarette smoking, advanced age, hyper-
lipidemia, and hypertension, are poor predictors of CV
events in PAD.23,24 Improved methods of risk classiﬁcation
to enhance proper PAD diagnosis and treatment are
needed. MMPs have attracted increasing interest in the
CV ﬁeld because they are involved in atherosclerotic plaque
formation, abdominal aortic aneurysm development, and
tissue remodeling in CLI.25,26 However, there is limited
knowledge about the pathophysiologic information they
can provide as potential biomarkers in PAD. MMP-2,
MMP-9, and MMP-8 have been shown to be increased
in PAD patients,9-12 but their utility as diagnostic and
prognostic tools has not been properly established. More-
over, the diverse functions and systemic sources of MMPs
argue for a careful examination of each family member in
CV pathologic processes. An association has been
described between circulating levels of MMP-10 and
different inﬂammatory markers, increased carotid intima-
media thickness, and the presence of carotid plaques in
subjects with subclinical atherosclerosis.13 Besides, patients
with disseminated intravascular coagulation, chronic kid-
ney disease, stroke, or diabetes present increased circulating
levels of MMP-10,15-18 suggesting a role in vascular path-
ologic processes associated with vascular remodeling and
inﬂammation. Likewise, this study reports increased levels
of MMP-10 independent of other risk factors in PAD pa-
tients, although other clinical parameters such as smoking,hypercholesterolemia, and diabetes were more strongly
associated with PAD. Accordingly, ROC curve analysis
showed only a moderate sensitivity and speciﬁcity for
MMP-10 in the identiﬁcation of PAD patients. Interest-
ingly, MMP-10 has been suggested to be a marker of
disease severity and poor outcome in atherosclerotic
and inﬂammatory pathologic processes.13,15,17,20 There-
fore, we focused the analysis of MMP-10 in PAD pa-
tients, showing elevated circulating levels of MMP-10
in association with traditional CV risk factors but not
with the atherosclerosis-associated inﬂammatory markers
CRP or ﬁbrinogen. However, an inverse correlation was
found between MMP-10 and ABI, the most commonly
used diagnostic test in PAD and also a marker of athero-
sclerotic burden with prognostic implications for CV
events.2 The association of MMP-10 with ABI supports
previous results showing its association with subclinical
and clinical atherosclerosis13,20 and its possible use as an
indicator of severity and risk for CV morbidity and mor-
tality in PAD. Whether the combined measurement of
MMP-10 and ABI could improve the diagnosis and pos-
terior treatment of those asymptomatic patients in whom
ABI is not yet altered or in patients at high risk of pre-
senting with an event should be further studied in long-
term studies.
PAD may be manifested as IC or CLI, the latter
conferring higher risk of death and CV events (20% to
25% of patients die at 1 year, and 25% to 30% undergo
Fig 2. Matrix metalloproteinase 10 (MMP-10) is associated with clinical outcome in peripheral arterial disease (PAD).
A, Circulating MMP-10 levels are increased in PAD patients who died. B and C, Kaplan-Meier estimates for cumulative
death (B) and amputation (C) in PAD patients in relation to MMP-10 tertiles (C, log-rank test, P < .05). D, Kaplan-
Meier estimates for cumulative cardiovascular (CV) mortality (log-rank test, P < .05).
JOURNAL OF VASCULAR SURGERY
Volume 61, Number 2 Martinez-Aguilar et al 433major amputation).27 As a more severe or unstable state,
CLI may be associated with increased matrix turnover,
inﬂammation, and endothelial stress, which can lead to
increased proteolytic activity. In agreement with a previous
study showing increased levels of MMP-9 in CLI pa-
tients,11 the current study reports signiﬁcantly higher levels
of MMP-10 and TIMP-1 in these patients. The observed
rise in circulating TIMP-1 could counterbalance the
increased proteolytic activity of vascular patients or reﬂect
the enhanced ﬁbrosis shown by CLI subjects.11
The current goals of symptomatic PAD management
are to eliminate or to reduce ischemic symptoms, to
avoid major amputation in the most severe cases, and
to prevent CV events (myocardial infarction, stroke, or
death) that result from widespread atherosclerosis.23
Different biochemical biomarkers, such as hs-CRP,
ﬁbrinogen, and amino-terminal pro-B-type natriuretic
peptide,23,28-30 have been evaluated as independent pre-
dictors of CV events and mortality in PAD. Even though
the measurement of these markers could be useful to
identify vulnerable patients, in some studies the addition
of these parameters to established risk factors improvestheir identiﬁcation only slightly.28 Moreover, the contri-
bution of those markers to predict adverse events varies
by the follow-up period (short-term vs longer term),29
age, or diabetic status.23 The evaluation of MMP-10 as
an early prognostic marker of mortality and CV events
in PAD showed an association with all-cause mortality
and CV mortality when it was examined separately.
These results suggest a contribution of MMP-10 to
the overall prediction of CV death in PAD, although
larger studies, in terms of number of patients and
follow-up period, should be designed to conﬁrm these
data.
PAD is a manifestation of systemic atherosclerosis,
and MMPs have been involved in all the steps of plaque
development. As previously reported in human carotid
atherosclerotic plaques,14 the morphologic analysis of
femoral arteries from PAD patients showed MMP-10
expression in rupture-prone regions, rich in macrophages,
within atherosclerotic plaques. Our current and previous
results indicate that systemic and local MMP-10 activity
may contribute to plaque rupture and its associated
complications.
Fig 3. Morphologic analysis showing matrix metalloproteinase 10 (MMP-10) expression in atherosclerotic femoral
arteries. A, Hematoxylin-eosin (HE) staining of femoral artery section. B, Higher magniﬁcation detail of HE-stained
sections. C and D, Immunohistochemistry for CD68 macrophage marker and a higher magniﬁcation detail (D). E and
F, Immunohistochemistry for MMP-10 and a higher magniﬁcation detail (F). Scale bar in A, C, and E denotes
250 mm. Scale bar in B, D, and F denotes 10 mm.
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not age matched. However, this variable was included
in the multivariate analysis, and MMP-10 remained
associated with PAD independently of other risk factors.
The mean follow-up period of 2.3 years is useful to esti-
mate early rather than long-term amputation and mor-
tality in PAD patients, and the role of MMP-10 as a
prognosis marker of CV events should be evaluated in
longer term studies. Some patients classiﬁed as noneCV
mortality died of unknown causes; thus, it could not be
determined whether in some cases they were also of CV
nature. Association analysis between baseline MMP-10
measurement and outcome in PAD has not taken into
account potential variations in MMP-10 during the
follow-up period. The usefulness of regular MMP-10
measurements as more accurate estimators for thesubsequent risk of PAD evolution, CV events, and mor-
tality should be assessed. The inﬂuence of medical treat-
ment, especially of statins, on MMP-10 levels should be
studied in larger cohorts of patients.
CONCLUSIONS
This study shows for the ﬁrst time that MMP-10 is
increased in PAD, in association with poor outcome, thus
representing a new marker of severity and prognosis in
PAD patients. Large prospective observational and clinical
trials targeting MMP-10 will provide new insights into the
pathogenesis and treatment of PAD.
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